295 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
INCY Incyte Corporation $67.04 $14.25B N/A
Article Searches
4 Toxic Stocks to Abandon or Sell Short for Solid Gains http://www.zacks.com/stock/news/366679/4-toxic-stocks-to-abandon-or-sell-short-for-solid-gains?cid=CS-ZC-FT-366679 Mar 29, 2019 - Overpriced toxic stocks are generally susceptible to outside shocks and burdened with a huge amount of debt.
Zacks.com featured expert Kevin Matras highlights: Incyte, AMC Entertainment, Covanta and U.S. Silica http://www.zacks.com/stock/news/359403/zackscom-featured-expert-kevin-matras-highlights-incyte-amc-entertainment-covanta-and-us-silica?cid=CS-ZC-FT-359403 Mar 14, 2019 - Zacks.com featured expert Kevin Matras highlights: Incyte, AMC Entertainment, Covanta and U.S. Silica
10 Stocks Powering S&P 500 ETF in the 10-Year Bull Run http://www.zacks.com/stock/news/359267/10-stocks-powering-sp-500-etf-in-the-10-year-bull-run?cid=CS-ZC-FT-359267 Mar 13, 2019 - Though most of the stocks in the S&P 500 ETF have delivered astounding returns during the decade, a few were the real stars, skyrocketing more than 2000%.
4 Toxic Stocks to Abandon or Sell Short for Solid Gains http://www.zacks.com/stock/news/359209/4-toxic-stocks-to-abandon-or-sell-short-for-solid-gains?cid=CS-ZC-FT-359209 Mar 13, 2019 - Overhyped toxic stocks are usually susceptible to external shocks and burdened with huge amount of debt.
Merck Gets CHMP Nod for Six-Week Dosing Option of Keytruda http://www.zacks.com/stock/news/357700/merck-gets-chmp-nod-for-six-week-dosing-option-of-keytruda?cid=CS-ZC-FT-357700 Mar 05, 2019 - Merck (MRK) gets CHMP recommendation for a six-week dosing schedule of Keytruda across all current monotherapy indications.
4 Toxic Stocks to Discard or Sell Short for Solid Gains http://www.zacks.com/stock/news/356949/4-toxic-stocks-to-discard-or-sell-short-for-solid-gains?cid=CS-ZC-FT-356949 Feb 26, 2019 - Overhyped toxic stocks are usually susceptible to external shocks and loaded with huge amount of debt.
Merck Gets Priority Review for Keytruda in Third-Line SCLC http://www.zacks.com/stock/news/355982/merck-gets-priority-review-for-keytruda-in-third-line-sclc?cid=CS-ZC-FT-355982 Feb 21, 2019 - Merck's (MRK) sBLA looking for approval of Keytruda monotherapy for the third-line treatment of small cell lung cancer, a difficult-to-treat cancer, gets FDA's priority review.
Merck's Keytruda Fails to Meet Endpoint in Liver Cancer Study http://www.zacks.com/stock/news/355533/mercks-keytruda-fails-to-meet-endpoint-in-liver-cancer-study?cid=CS-ZC-FT-355533 Feb 20, 2019 - Merck's (MRK) Keytruda fails a phase III study in second-line advanced hepatocellular carcinoma (HCC). It gets FDA approval for the adjuvant treatment of patients with high-risk stage III melanoma.
Merck Gets Priority Review for Keytruda Combo in Kidney Cancer http://www.zacks.com/stock/news/355193/merck-gets-priority-review-for-keytruda-combo-in-kidney-cancer?cid=CS-ZC-FT-355193 Feb 18, 2019 - Merck's (MRK) sBLA looking for approval of Keytruda plus Pfizer's Inlyta for the first-line treatment of the most common type of kidney cancer gets FDA's priority review.
Incyte Corporation (INCY) CEO Hervé Hoppenot on Q4 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4241318-incyte-corporation-incy-ceo-herve-hoppenot-q4-2018-results-earnings-call-transcript?source=feed_sector_healthcare Feb 14, 2019 - Incyte Corporation (NASDAQ:INCY) Q4 2018 Results Conference Call February 14, 2019 08:00 AM ET Company Participants Mike Booth - VP, IR Hervé Hoppenot - President and CEO Barry Flannelly - EVP, Genera

Pages: 1...345678910111213...30

<<<Page 8>